Switch theme
Sign up to access all valuation multiples
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
2011
22
LTM Revenue $19.3M
LTM EBITDA $9.5M
$89.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Saniona has a last 12-month revenue (LTM) of $19.3M and a last 12-month EBITDA of $9.5M.
In the most recent fiscal year, Saniona achieved revenue of $34.5M and an EBITDA of $22.9M.
Saniona expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Saniona valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $19.3M | XXX | $34.5M | XXX | XXX | XXX |
| Gross Profit | $19.0M | XXX | $34.0M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $9.5M | XXX | $22.9M | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 66% | XXX | XXX | XXX |
| EBIT | $8.7M | XXX | $24.7M | XXX | XXX | XXX |
| EBIT Margin | 45% | XXX | 71% | XXX | XXX | XXX |
| Net Profit | $5.6M | XXX | $19.5M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 56% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Saniona's stock price is SEK 8 (or $1).
Saniona has current market cap of SEK 1.1B (or $115M), and EV of SEK 863M (or $89.1M).
See Saniona trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $89.1M | $115M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Saniona has market cap of $115M and EV of $89.1M.
Saniona's trades at 2.6x EV/Revenue multiple, and 3.9x EV/EBITDA.
Equity research analysts estimate Saniona's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Saniona has a P/E ratio of 20.4x.
See valuation multiples for Saniona and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $115M | XXX | $115M | XXX | XXX | XXX |
| EV (current) | $89.1M | XXX | $89.1M | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.4x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBIT | 10.3x | XXX | 3.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.4x | XXX | 5.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSaniona's last 12 month revenue growth is -96%
Saniona's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $0.4M for the same period.
Saniona's rule of 40 is -583% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Saniona's rule of X is -191% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Saniona and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -96% | XXX | -81% | XXX | XXX | XXX |
| EBITDA Margin | 49% | XXX | 66% | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -583% | XXX | -30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -191% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Saniona acquired XXX companies to date.
Last acquisition by Saniona was XXXXXXXX, XXXXX XXXXX XXXXXX . Saniona acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Saniona founded? | Saniona was founded in 2011. |
| Where is Saniona headquartered? | Saniona is headquartered in Sweden. |
| How many employees does Saniona have? | As of today, Saniona has 22 employees. |
| Who is the CEO of Saniona? | Saniona's CEO is Mr. Thomas Feldthus. |
| Is Saniona publicy listed? | Yes, Saniona is a public company listed on STO. |
| What is the stock symbol of Saniona? | Saniona trades under SANION ticker. |
| When did Saniona go public? | Saniona went public in 2014. |
| Who are competitors of Saniona? | Similar companies to Saniona include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Saniona? | Saniona's current market cap is $115M |
| What is the current revenue of Saniona? | Saniona's last 12 months revenue is $19.3M. |
| What is the current revenue growth of Saniona? | Saniona revenue growth (NTM/LTM) is -96%. |
| What is the current EV/Revenue multiple of Saniona? | Current revenue multiple of Saniona is 4.6x. |
| Is Saniona profitable? | Yes, Saniona is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Saniona? | Saniona's last 12 months EBITDA is $9.5M. |
| What is Saniona's EBITDA margin? | Saniona's last 12 months EBITDA margin is 49%. |
| What is the current EV/EBITDA multiple of Saniona? | Current EBITDA multiple of Saniona is 9.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
